Literature DB >> 2553921

Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.

M A Gistrak1, D Paul, E F Hahn, G W Pasternak.   

Abstract

NalBzoH (6-desoxy-6-benzoylhydrazido-N-allyl-14-hydroxydihydronomorphin one) is a novel opiate with potent actions at both mu and kappa receptors. Analgesic studies in mice examining increasing doses of NalBzoH with a fixed dose of morphine revealed a biphasic curve. NalBzoH at doses as low as 1 microgram/kg partially antagonized morphine analgesia. Higher NalBzoH doses continued to inhibit morphine analgesia in a dose-dependent manner, with the 1-mg/kg dose antagonizing completely morphine analgesia. As the NalBzoH dose increased beyond 1 mg/kg analgesia returned. NalBzoH also prduced a similar analgesic response when administered alone in mice and also was active in rats. NalBzoH had excellent p.o. activity, with an analgesic potency in mice equivalent to s.c. administration. Naloxone reversed NalBzoH analgesia far less effectively than morphine analgesia. In contrast, Win44,441 antagonized both morphine and NalBzoH analgesia with a similar potency, consistent with a kappa mechanism for NalBzoH analgesia. Repeated administration of NalBzoH resulted in tolerance. There was no analgesic cross-tolerance between NalBzoH and either morphine or the kappa 1-selective agent U50,488H, implying a selective kappa 3 mechanism of analgesia. In addition to blocking morphine analgesia, low doses of NalBzoH also partially reversed the inhibition of gastrointestinal transit in mice produced by morphine, antagonized completely morphine lethality and precipitated withdrawal in morphine-dependent mice, confirming its antagonist activity in mu receptors. The duration of NalBzoH's kappa and mu actions differed dramatically. In mice, analgesia typically lasted less than 2 hr whereas the same NalBzoH dose antagonized completely morphine analgesia, a mu action, for 16 hr. Full sensitivity to morphine did not return for 32 hr.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553921

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants.

Authors:  Susruta Majumdar; Joan Subrath; Valerie Le Rouzic; Lisa Polikar; Maxim Burgman; Kuni Nagakura; Julie Ocampo; Nathan Haselton; Anna R Pasternak; Steven Grinnell; Ying-Xian Pan; Gavril W Pasternak
Journal:  J Med Chem       Date:  2012-07-16       Impact factor: 7.446

2.  The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.

Authors:  Diana Vivian Atigari; Kelly Frances Paton; Rajendra Uprety; András Váradi; Amy Frances Alder; Brittany Scouller; John H Miller; Susruta Majumdar; Bronwyn Maree Kivell
Journal:  Neuropharmacology       Date:  2020-12-28       Impact factor: 5.250

3.  Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin.

Authors:  S Sbrenna; M Marti; M Morari; G Calo'; R Guerrini; L Beani; C Bianchi
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.

Authors:  Susruta Majumdar; Steven Grinnell; Valerie Le Rouzic; Maxim Burgman; Lisa Polikar; Michael Ansonoff; John Pintar; Ying-Xian Pan; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

5.  Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.

Authors:  Maria C Olianas; Danilo Concas; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Oxidative Metabolism as a Modulator of Kratom's Biological Actions.

Authors:  Soumen Chakraborty; Rajendra Uprety; Samuel T Slocum; Takeshi Irie; Valerie Le Rouzic; Xiaohai Li; Lisa L Wilson; Brittany Scouller; Amy F Alder; Andrew C Kruegel; Michael Ansonoff; Andras Varadi; Shainnel O Eans; Amanda Hunkele; Abdullah Allaoa; Sanjay Kalra; Jin Xu; Ying Xian Pan; John Pintar; Bronwyn M Kivell; Gavril W Pasternak; Michael D Cameron; Jay P McLaughlin; Dalibor Sames; Susruta Majumdar
Journal:  J Med Chem       Date:  2021-11-16       Impact factor: 7.446

7.  Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor.

Authors:  Y A Kolesnikov; C G Pick; G Ciszewska; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

8.  Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.

Authors:  Steven G Grinnell; Susruta Majumdar; Ankita Narayan; Valerie Le Rouzic; Michael Ansonoff; John E Pintar; Gavril W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  2014-06-26       Impact factor: 4.030

Review 9.  Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.

Authors:  Nurulain Zaveri
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

Review 10.  Interactive Mechanisms of Supraspinal Sites of Opioid Analgesic Action: A Festschrift to Dr. Gavril W. Pasternak.

Authors:  Grace C Rossi; Richard J Bodnar
Journal:  Cell Mol Neurobiol       Date:  2020-09-24       Impact factor: 5.046

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.